Yasmin 28 (Ethinyl Estradiol/Drospirenone) Patent Expiration, LOE Window & CMS Spending

Yasmin 28 (Ethinyl Estradiol/Drospirenone) by Bayer: Off-Patent Genericized (AB Competition), 18 AB generics, $728K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$728K
2024 Medicare Part D Spend$44K
2024 Medicaid Spend$684K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.